37864041|t|TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC.
37864041|a|Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive type of breast cancer with a poor prognosis and a high recurrence rate. Chemotherapy is still the mainstay of treatment for cancer patients without a genetic BRCA mutation, despite the approval of Olaparib, an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. Tripartite motif containing-21 (TRIM21) is one of the TRIM family members that has been investigated in various types of cancer. Here, we found that a low TRIM21 expression level was correlated with poor overall survival of TNBC patients. Knockout of TRIM21 promoted the proliferation of TNBC cells in vivo and in vitro, as well as migratory and invasive capabilities in vitro. Importantly, breast cancer susceptibility gene 1 (BRCA1) was identified as a ubiquitination substrate of TRIM21. It was confirmed that BRCA1 was upregulated after Olaparib treatment, which may explain the relative resistance of BRCA1-proficient TNBC cells to Olaparib. Moreover, Sorafenib, a standard treatment for hepatocellular carcinoma, increased the sensitivity of TNBC cells to Olaparib by promoting TRIM21-mediated ubiquitination degradation of BRCA1. Thus, a synergic effect of Olaparib and Sorafenib was found in vitro and in vivo. This combined treatment also aggravated DNA damage, cell cycle arrest, and apoptosis of TNBC cells. In summary, the findings verified the synergistic effect of Olaparib and Sorafenib and revealed TRIM21 as a potential target for TNBC therapy.
37864041	0	6	TRIM21	Gene	6737
37864041	42	50	Olaparib	Chemical	MESH:C531550
37864041	55	64	Sorafenib	Chemical	MESH:D000077157
37864041	78	83	BRCA1	Gene	672
37864041	110	114	TNBC	Disease	MESH:D064726
37864041	116	145	Triple-negative breast cancer	Disease	MESH:D064726
37864041	147	151	TNBC	Disease	MESH:D064726
37864041	195	208	breast cancer	Disease	MESH:D001943
37864041	311	317	cancer	Disease	MESH:D009369
37864041	345	349	BRCA	Gene	672
37864041	384	392	Olaparib	Chemical	MESH:C531550
37864041	414	442	poly (ADP-ribose) polymerase	Gene	142
37864041	444	448	PARP	Gene	142
37864041	458	488	Tripartite motif containing-21	Gene	6737
37864041	490	496	TRIM21	Gene	6737
37864041	512	516	TRIM	Gene	50852
37864041	579	585	cancer	Disease	MESH:D009369
37864041	613	619	TRIM21	Gene	6737
37864041	682	686	TNBC	Disease	MESH:D064726
37864041	709	715	TRIM21	Gene	6737
37864041	746	750	TNBC	Disease	MESH:D064726
37864041	886	891	BRCA1	Gene	672
37864041	941	947	TRIM21	Gene	6737
37864041	971	976	BRCA1	Gene	672
37864041	999	1007	Olaparib	Chemical	MESH:C531550
37864041	1064	1069	BRCA1	Gene	672
37864041	1081	1085	TNBC	Disease	MESH:D064726
37864041	1095	1103	Olaparib	Chemical	MESH:C531550
37864041	1115	1124	Sorafenib	Chemical	MESH:D000077157
37864041	1151	1175	hepatocellular carcinoma	Disease	MESH:D006528
37864041	1206	1210	TNBC	Disease	MESH:D064726
37864041	1220	1228	Olaparib	Chemical	MESH:C531550
37864041	1242	1248	TRIM21	Gene	6737
37864041	1288	1293	BRCA1	Gene	672
37864041	1322	1330	Olaparib	Chemical	MESH:C531550
37864041	1335	1344	Sorafenib	Chemical	MESH:D000077157
37864041	1465	1469	TNBC	Disease	MESH:D064726
37864041	1537	1545	Olaparib	Chemical	MESH:C531550
37864041	1550	1559	Sorafenib	Chemical	MESH:D000077157
37864041	1573	1579	TRIM21	Gene	6737
37864041	1606	1610	TNBC	Disease	MESH:D064726
37864041	Association	MESH:D009369	6737
37864041	Negative_Correlation	MESH:D000077157	MESH:D006528
37864041	Association	MESH:C531550	6737
37864041	Negative_Correlation	MESH:C531550	MESH:D064726
37864041	Negative_Correlation	MESH:C531550	MESH:D006528
37864041	Association	MESH:D000077157	6737
37864041	Positive_Correlation	672	6737
37864041	Negative_Correlation	MESH:D000077157	MESH:D064726
37864041	Association	MESH:C531550	672
37864041	Cotreatment	MESH:C531550	MESH:D000077157
37864041	Negative_Correlation	MESH:D000077157	672
37864041	Association	MESH:D064726	6737
37864041	Negative_Correlation	MESH:C531550	142

